Dear Editor,

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), characterized by co-expression of CD4 and CD56 without any other lineage-specific markers, is an aggressive tumor type that shows a high frequency of skin involvement and nodal or marrow infiltration with a propensity toward leukemic dissemination \[[@B1]\].This disease was formerly defined by the World Health Organization as blastic NK-cell lymphoma, and was later grouped with AML and related precursor neoplasms \[[@B2]\]. Here we report two AML cases with *KMT2A* (or *MLL*) rearrangements along with CD4+/CD56+ expression, which had the potential to be misdiagnosed as BPDCN.

A 59-yr-old man presented with erythematous papules and vesicles on his whole body for one week. Complete blood counts showed anemia (Hb, 80 g/L), thrombocytopenia (62×10^9^ platelets/L), and many circulating plasmoblast-like cells (65%). Bone marrow examination showed hypercellular marrow (90%) mostly composed of plasmoblast-like cells with coarse nuclear chromatin, distinct nucleoli, and abundant basophilic cytoplasm ([Fig. 1A](#F1){ref-type="fig"}). Flow cytometry revealed that the neoplastic cells were positive for CD4, CD33, CD38, CD56, CD117, and CD138 ([Fig. 1B](#F1){ref-type="fig"}), and negative for other myeloid or lymphoid markers ([Table 1](#T1){ref-type="table"}). Skin lesions showed diffuse infiltration of medium- to large-sized agranular blastic cells with CD4 and CD56 co-expression ([Fig. 1C](#F1){ref-type="fig"}). Bone marrow and skin were negative for CD123 immunohistochemical stain. The chromosome study revealed 45,X,-Y\[9\]/46,XY\[11\] without 11q23 abnormalities. Multiplex, nested reverse transcription (RT)-PCR was performed for screening and detection of 28 chromosomal translocations using the HemaVision kit (DNA Technology, Research Park, Aarhus, Denmark), and the presence of *MLL-MLLT10* rearrangement was demonstrated. It was confirmed by direct sequencing ([Fig. 1D](#F1){ref-type="fig"}). Fluorescence *in situ* hybridization for *MLL* rearrangement revealed nuc ish(5\'MLLx3,3\'MLLx2)(5\'MLL con 3\'MLLx2)\[170/200\], suggesting the presence of an atypical *MLL* breakpoint. Although the lineage antigens expressed here were not specific to AML, he was diagnosed as having AML with *MLL* rearrangement in bone marrow and skin.

A 30-yr-old woman presented with multiple lymphadenopathy for three weeks. Laboratory analysis revealed anemia (Hb, 81 g/L), thrombocytopenia (82×10^9^ platelets/L), and leukocytosis (16.77×10^9^ white blood cells/L) with circulating plasmacytoid cells (63%). Neither skin lesion nor monoclonal gammopathy was present. Bone marrow analysis showed hypercellular marrow (100%) with leukemic cells containing abundant basophilic cytoplasm ([Fig. 1E](#F1){ref-type="fig"}). Flow cytometry revealed that the neoplastic cells were positive for CD4, CD7, CD33, CD38, CD56, and CD64, ([Fig. 1F](#F1){ref-type="fig"}), and were negative for other markers ([Table 1](#T1){ref-type="table"}). The cytochemical stain for non-specific esterase in neoplastic cells was negative. Immunohistochemical stains of bone marrow biopsy specimens showed that the neoplastic cells were negative for CD123, CD138, kappa, and lambda. Lymph node biopsy analysis demonstrated that the neoplastic cells co-expressing CD4 and CD56 were negative for CD123. Cytogenetic analysis revealed 46,XX,t(9;11)(p22;q23),t(9;21)(q12;p11.2)\[20\]. The *MLL-MLLT3* rearrangement was detected by RT-PCR. Although adequate lineage-specific markers were not observed, she was diagnosed as having an AML with *MLL* rearrangement in bone marrow and lymph nodes.

So far, three cases of CD4+/CD56+ hematologic malignancies with *MLL* rearrangements have been reported as rare cases of BPDCN with *MLL* rearrangement ([Table 1](#T1){ref-type="table"}). The leukemic cells reported in the literature expressed the myeloid and monocytic markers CD33, CD117, CD11c, CD15, or CD64, which were not specific enough to identify a specific lineage \[[@B3][@B4][@B5]\]. These three cases did not express highly specific plasmacytoid dendritic cell-associated antigens, such as CD123, TCL1, CD2AP, or CD303 (BDCA2); therefore, additional immunohistochemical studies were necessary at their diagnosis. Variable expression of CD4 or CD56 in adult AML cases with *MLL* rearrangement has been reported \[[@B6]\], and BPDCN is often confused with monocytic leukemias. Based on the limited information on immunophenotypes of these cases, *MLL*-related monocytic leukemia would be a reasonable diagnosis ([Table 1](#T1){ref-type="table"}).

This study emphasizes that the diagnosis of BPDCN should only be considered after a full investigation of plasmacytoid dendritic cell markers, ensuring there is no expression of myeloid or monocytic markers on the blasts \[[@B7]\]. Since hematologic neoplasms such as BPDCN, AML, extranodal NK/T cell lymphoma, nasal type, and mature T cell lymphomas with or without skin involvement may express CD56 with or without CD4, extensive immunohistochemical and genetic analyses are necessary before definitively diagnosing BPDCN or AML \[[@B8][@B9]\].

In conclusion, CD4+/CD56+ hematologic malignancies can be suspected to be BPDCN, and clinicians should conduct a full analysis including flow cytometry for adequate myeloid/monocytic markers, immunohistochemical stain for highly specific plasmacytoid dendritic cell-associated antigens, cytogenetic, and genetic studies to make an exact diagnosis and determine effective treatment.
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![Morphological features, flow cytometric analysis, immunohistochemical stain, and genetic study of the two cases of CD4+/CD56+AML. (A) Plasmoblast-like neoplastic cells in the first case (Wright Giemsa stain, 400×, Bone marrow); (B) Immunophenotyping features with CD56 and CD4 coexpression in the first case; (C) Skin biopsy showing diffuse infiltration of medium- to large-sized agranular blastic cells into the dermis in the first case (Hematoxylin and Eosin stain, 100×, Skin lesion); (D) The *MLL-MLLT10* rearrangement confirmed by direct sequencing in the first case; (E) Plasmacytoid cells in the second case (Wright Giemsa stain; ×400, Bone marrow); and (F) The immunophenotyping features with CD4 and CD56 coexpression in the second case.](alm-36-494-g001){#F1}

###### The clinicopathologic characteristics of CD4+/CD56+ hematologic malignancies carrying the *MLL* rearrangement

![](alm-36-494-i001)

                                   Case 1                                                                                 Case 2                                                                          Case 3                                                                            Case 4                                                              Case 5
  -------------------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Reference                        \[[@B3]\]                                                                              \[[@B4]\]                                                                       \[[@B5]\]                                                                         First case in this study                                            Second case in this study
  Diagnosis                        CD4+/CD56+ hematodermic malignancy                                                     BPDCN with *MLL-ENL* rearrangement                                              BPDCN with *MLL* rearrangement                                                    AML with *MLL* rearrangement                                        AML with *MLL* rearrangement
  Age/gender                       50/F                                                                                   45/M                                                                            8/F                                                                               59/M                                                                30/F
  Race                             China                                                                                  Japan                                                                           Korea                                                                             Korea                                                               Korea
  Chief complaint                  Not described                                                                          Multiple disseminated skin nodules                                              Mild fatigue and petechiae on extremities                                         Multiple skin rash                                                  Multiple lymphadenopathy
  Skin lesion                      Yes                                                                                    Yes                                                                             No                                                                                Yes                                                                 No
  Circulating tumor cells          No                                                                                     Yes                                                                             Yes                                                                               Yes                                                                 Yes
  Bone marrow involvement          Yes                                                                                    Yes                                                                             Yes                                                                               Yes                                                                 Yes
  Flow cytometric positivity       CD4, CD45, CD56                                                                        CD4, CD11c, CD33, CD45RA, CD56, CD68, CD117, CD123, HLA-DR                      CD4, CD15, CD33, CD56, CD64, CD117, HLA-DR, TdT                                   CD4, CD33, CD38, CD45, CD56, CD117, CD138                           CD4, CD7, CD33, CD38, CD45, CD56, CD64,
  Flow cytometric negativity       CD2, CD3, CD5, CD7, CD8, CD10, CD13, CD14, CD19, CD20, CD22, CD23, CD34, HLA-DR, MPO   CD3, cCD3, CD5, CD7, CD8, CD10, CD11b, CD13, CD19, CD20, CD34, cMPO             CD2, CD3, cCD3, CD5, CD7, CD10, CD13, CD14, CD16, CD19, CD20, cCD22, CD34, cMPO   CD2, CD3, CD5, CD7, CD10, CD13, CD14, CD19, CD20, CD34, cMPO, TdT   CD3, CD5, CD8, CD10, CD11b, CD13, CD14, CD19, CD20, CD34, cCD79a, CD117, CD138, cMPO, kappa, lambda, TdT
  Karyotype                        46, XX,t(4;9;11)(q12;p22;q23) \[18\]/46, XX \[10\]                                     49, XY, +add(1)(p13), +8, +8,t(11;19)(q23;p13.3)\[20\]                          48,XX,+8,t(11;19)(q23;p13.3),+19\[20\]                                            45,X,-Y\[9\]/46,XY\[11\]                                            46,XX,t(9;11)(p22;q23),t(9;21)(q12;p11.2)\[20\]
  FISH, *MLL* gene rearrangement   Detected                                                                               Detected                                                                        Detected                                                                          Detected atypical MLL breakpoint                                    Detected
  RT-PCR for *MLL*                 *MLL-MLLT3*                                                                            *MLL-ELN*                                                                       *MLL-MLLT1*                                                                       *MLL-MLLT10*                                                        *MLL-MLLT3*
  Treatment                        CHOP combination chemotherapy and allogeneic bone marrow transplantation               After failure of CHOP chemotherapy, acute leukemia-type chemotherapy was done   Induction chemotherapy (daunorubicin, vincristine, prednisolone, and cytarabin)   Induction chemotherapy (daunorubicin and cytarabin)                 Induction chemotherapy (daunorubicin and cytarabin) and allogeneic stem cell transplantation

Abbreviations: BPDCN, blastic plasmacytoid dendritic cell neoplasm; RT-PCR, reverse transcription-PCR; cMPO, cytoplasmic myeloperoxidase; TdT, terminal deoxynucleotidyl transferase; CHOP, cyclophosphamide, vincristine, epirubicin, and prednisolone.
